132 - E<strong>le</strong>menti di NEUROSCIENZE E DIPENDENZE 35. Hertling I., Ramskog<strong>le</strong>r K., Rieg<strong>le</strong>r A., Walter H., Mader R. & Lesch O.M. (2001). Craving for alcohol and prevention of relapse. Wiener Klinische Wochenschrift, 113, 717-726. 36. Irwin M., Schuckit M. & Smith T. L. (1990). Clinical importance of age at onset in type I and type II primary alcoholics. Archives of General Psychiatry, 47, 320-333. 37. Janiri L., Calvosa F., Dario T., Pozzi G., Ruggeri A., Addolorato G., et al. (2004). The Italian version of the obsessive-compulsive drinking sca<strong>le</strong>: Validation, comparison with the other versions and difference between type 1- and type 2-like alcoholics. Drug and Alcohol Dependence, 74, 187-195. 38. Johnson B.A., Ait-Daoud N., Bowden C.L., DiC<strong>le</strong>mente C.C., Roache J.D., Lawson K., Javors M.A. & Ma J.Z. (2003). Oral topiramate for treatment of alcohol dependence: a randomised control<strong>le</strong>d trial. Lancet, 361, 1677-1685. 39. Johnson B.A., Rosenthal N., Capece J.A., Wiegand F., Mao L., Beyers K. et al. (2007). Topiramate for treating alcohol dependence: a randomized control<strong>le</strong>d trial. JAMA, 298, 1641-1651. 40. Johnson B.A., Rosenthal N., Capece J.A., Wiegand F., Mao L., Beyers K., et al. (2008). Topiramate improves the physical health and quality of life of alcohol-dependent individuals: the U.S. multi-site randomized control<strong>le</strong>d trial. Archives of Internal Medicine, 168, 1188-1199. 41. Koob G.F. (1992). Drugs of abuse: Anatomy, pharmacology and function of reward pathways. Trends in Pharmacological Sciences, 13, 177-184. 42. Korpi E.R., Sinclair J.D. & Malminen O. (1987). Dopamine D2 receptor binding in striatal membranes of rat lines se<strong>le</strong>cted for differences in alcohol-related behaviours. Pharmacology and Toxicology, 61, 94-97. 43. Kranz<strong>le</strong>r H.R. & Van Kirk J. (2001). Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis. Alcoholism: Clinical and Ex<strong>per</strong>imental Research, 25, 1335-1341. 44. Litt M.D., Cooney N.L. & Morse P. (2000). Reactivity to alcohol-related stimuli in the laboratory and in the field: Predictors of craving in treated alcoholics. Addiction, 95, 889-900. 45. Love A., James D., & Willner P. (1998). A comparison of two alcohol craving questionnaires. Addiction, 93, 1091-1102. 46. Marlatt G.A. & Gordon J. R. (1985). Relapse prevention: Maintenance strategies for addictive behaviours. New York: Guildford Press. 47. Merck’s manual of the Materia Medica. (1899). New York: Merck and Company. 48. Mereu G. & Gessa G.L. (1985). Low does of ethanol inhibit the firing of neurons in the substantia nigra, pars reticulata: A GABAergic effect Brain Research, 360, 325-330. 49. Meyer R.E. (2000). Craving: What can be done to bring the insights of neuroscience, behavioral science and clinical science into synchrony. Addiction, 95(Suppl. 2), S219-S227. 50. Modell J.G., Glaser F.B., Cyr L. & Mountz J.M. (1992). Obsessive and compulsive characteristics of craving for alcohol in alcohol abuse and dependence. Alcoholism: Clinical and Ex<strong>per</strong>imental Research, 16, 272-274. 51. Monti P.M., Rohsenow D.J. & Hutchison K.E. (2000). Toward bridging the gap between biological, psychobiological and psychosocial models of alcohol craving. Addiction, 95(Suppl. 2), S229-S236. 52. Niaura R., Cognitive social <strong>le</strong>arning and related <strong>per</strong>spectives on drug craving. Addicton, 2000 Aug; 95 Suppl 2:S155-63. 53. Niaura R.S., Rohsenow D.J., Binkoff J.A., Monti P.M., Pedraza M. & Abrams D.B. (1988). 54. Re<strong>le</strong>vance of cue reactivity to understanding alcohol and smoking relapse. Journal of Abnormal Psychology, 97, 133-152. 55. Pail<strong>le</strong> F.M., Guelfi G.B., Perkins A.C., et al. (1995). Doub<strong>le</strong>-blind randomized multicentre trial of acamprosate in maintaining abstinence from alcohol. Alcohol and Alcoholism, 30, 239-247. 56. Potgieter A.S., Deckers F. & Geerlings P. (1999). Craving and relapse measurement in alcoholism. Alcohol and Alcoholism, 34, 254-260. 57. Schachter S., & Singer J.E. (1962). Cognitive, social and physiological determinants of emotional state. Psychological Review, 69, 379-399. 58. Sinha R. & O’Mal<strong>le</strong>y S. (1999). Craving for alcohol: findings from the clinic and the laboratory. Alcohol and Alcoholism, 34, 223-230. 59. Spanagel R. (2003). The ro<strong>le</strong> of the glutamatergic system in alcohol addiction. Fortschritte der Neurologie-Psychiatrie, 71(Suppl. 1), S33- S35. 60. Srisurapanont, M., and Jarusuraisin, N. (2005). Naltrexone for the treatment of alcoholism: a meta-analysis of randomized control<strong>le</strong>d trials. International Journal of Neuropsychopharmacology, 8, 267-280. 61. Stella L., Addolorato G., Rinaldi B., Capuano A., Berrino L., Rossi F. & Maione S. (2008). An open randomized study of the treatment of escitalopram alone and combined with gamma-hydroxybutyric acid and naltrexone in alcoholic patients. Pharmacological Research, 57, 312- 317. 62. Stockwell T., Hodgson R., Edwards G., Taylor C. & Rankin H. (1979). The development of a questionnaire to measure severity of alcohol dependence. British Journal of Addiction to Alcohol and to Other Drugs, 74, 79-87. 63. Tiffany, S.T. (1990). A cognitive model of drug urges and drug-use behavior: Ro<strong>le</strong> of automatic and nonautomatic processes. Psychological Review, 97, 147-168. 64. Trachtenberg M.C. & Blum K. (1987). Alcohol and opioid peptides: Neuropharmacological rationa<strong>le</strong> for physical craving of alcohol. American Journal of Drug and Alcohol Abuse, 13, 365-372. 65. Verheul R., Van Den Brink W. & Geerlings P. (1999). A three-pathway psychological model of craving for alcohol. Alcohol and Alcoholism, 34, 197-222. 66. Walter H., Ramskog<strong>le</strong>r K., Sem<strong>le</strong>r B., Lesch O.M. & Platz W. (2001). Dopamine and alcohol relapse: D1 and D2 antagonists increase relapse rates in animal studies and clinical trials. Journal of Biomedical Science, 8, 83-88. 67. Whitworth A.B., Fischer F., Lesch O.M., Nimmerrichter A., Oberbauer H., Platz T., Potgieter A., Walter H., F<strong>le</strong>ischhacker W.W. (1996). Comparison of acamprosate and placebo in long-term treatment of alcohol dependence. Lancet, 347, 1438-1442. 68. WHO Export Committee on Mental Health and on Alcohol (1955). The “craving” for alcohol. Quarterly Journal of Studies on Alcohol, 16, 33-66. 69. Wiesbeck G.A., Mauerer C., Thome J., Jakob F., & Boening J. (1995). Alcohol dependence, family history, and D2 dopamine receptor function as neuroendocrinologically assessed with apomorphine. Drug and Alcohol Dependence, 40, 49-53. 70. Wik<strong>le</strong>r A. (1948). Recent progress in research on the neurophysiological basis of the morphine addiction. American Journal of Psychiatry, 105, 328-338. 71. Wright F.D., Beck A.T., Newman C.F., & Liese B.S. (1993). Cognitive therapy of substance abuse: Theoretical rationa<strong>le</strong>. NIDA Research Monograph, 137, 123-146.
Neuroimaging